Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial Alliance A091201

Title
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Principal Investigator
Timothy Kuzel
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.Alliance A091201
Purpose
The purpose of this study is to test whether the new treatment with an experimental drug, known as cabozantinib is more effective than chemotherapy for treating ocular melanoma.
Overview
Cabozantinib may work by blocking a protein called MET which is often found to be an important cause of the growth and spread of ocular melanoma.
Eligibility
Some of the eligibility criteria include:
  • Participants must have ocular melanoma that has spread beyond the eye and/or it cannot be removed with surgery.
  • Prior treatment is allowed, with the exception of drugs that target specific cell receptors. Please discuss all prior treatments with the study doctor.
  • Participants must be 18 or older.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Participants will be "randomized" into one of the study groups described below. Those in Group 1 (often called "Arm 1") will receive cabozantinib. Cabozantinib is taken by mouth every day of a 28-day cycle. Those in Group 2 (often called "Arm 2") will receive temozolomide (or dacarbazine if temozolomide is not available). Temozolomide is taken by mouth on days 1-5 of a 28 days cycle. If temozolomide is not available, dacarbazine may be given as a replacement. If this happens dacarbazine will be given by intravenous (IV) (through a needle or tube inserted into a vein) infusion on day 1 of a 21-day cycle.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Timothy Kuzel

last updated: 25-Oct-14 09:53 PM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.